Trust me, trust no one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Damn this mornings action was awesome!!!! Tooks some fast nice profits and now reload a little. Boom 1.71 in the first 10 minutes was crazy. Short getting got! Looking forward to the conference call! OMG those .30-.40 buys, damn those were sweeet buys, lets go!
$$$LPTV$$$
What a close!!! Shortie covering its so sweet! Was nice accumulating in the .30-.50 range while it lasted. Looking forward to conference call on Tuesday. $$$
What a close!!! Shortie covering its so sweet! Was nice accumulating in the .30-.50 range while it lasted. Looking forward to conference call on Tuesday. $$$
Harom on today 1 pm EST
Today: Join @ChadHarmanCEO at 1PM ET in the #MarketMasters Room with @RagingBull for an exclusive interview to discuss @Psycheceutical's latest progress and the state of the psychedelic drug-delivery market.
— Psycheceutical (@psycheceutical) October 19, 2023
➡️ https://t.co/LcW7iwiDR7$BWVI #mentalhealth #biotech
Hardly, just dealing with the ones that actually need to chill and are loose cannons. Don't be super daft.
So you answer is to whine incessantly like an infant day in and day out? Wow, so pathetic.
And you state you don't believe them, but still going to whine and act like you know understand jack shit about running a business?
Your daily myopia is pathetic, how much exactly did you invest here? $500? Clearly you can't afford to invest in the high risk OTC
arena, seeing how this has affected you. You should be spending a lot more time assessing yourself over this investment.
I've never taken the pedestal. I've always stated OTC is high risk high reward, so invest accordingly. By you incessant daily whining
clearly you have issues on many levels.
Stop being a freaking whiny pussy, and talk to management, stop making excuses for yourself and your life, as at this point
anything you are feeling and bitching about is 100% your fault.
Go reassess your life, jesus christ you sad sack lame excuse for an adult.
So in other words ‘yes im a keyboard coward who will continue to whine on anonymously, but have no spine to actually have a real conversation’ got it.
Great Annual, KPIs continue to improve, solid revenues and growth continues to head in the right direction.
Back to ignore you go, coward.
Great new investor deck as well. Continuing down the path they set out to do.
https://psycheceutical.com/investor-relations/
Well here is the problem. You post your whines daily and make all these accusations, yet you refuse to actually have a chat with the CEO. You can make all the excuses you want, but everything you say loses all integrity when you hide behind a keyboard when offered a path forward.
I even took the time to write to the CEO on your behalf to ask they reach out to you, or have you call. Yet, all you did was say 'No!' with some pathetic excuse
why you couldn't face the ones you accuse.
Your posts are consistently inaccurate, and just over the top whining, like that is going to solve any business issue.
Add value to society, don't be a punk.
Call the CEO, been waiting.
Until then, nothing you say means squat.
Yes thanks. Haters going to hate. The company still here especially after pandemic and so many small companies failed. Remember all the cries of bankruptcy? Never close to reality. We continue to grow, and build the brand. Opportunities abound, and the KPI’s are reflecting all the efforts.
Remember it’s always 1000 times harder to create and destroy. The haters and trolls never create, they just spend their life trying to destroy what others create. It doesn’t matter they’re hypocrites, lying and cheating themselves while attacking and putting falsities into their narrative.
We are still here and doing quite well, moving up as the brand gain strength, and the number of locations continues to climb.
Yes, there will be plenty of trials and tribulations as there are with any growth company. Now and in the future, but as the KPI’s show the last 8 Qs are the facts, and we aren’t slowing down.
As always, looking forward to the next update!
Oh they always come crawling out of the sewer for my posts lol
Great Annual! Almost 50% increase in revs, and we talking $9 Million! How rare is that pinks? :)
We will be off them in the future. For now, our engine keeps revving as we add locations and KPIs get better and better.
COGS is going down too it looks like! That is awesome, meaning all the efforts to streamline operations is really paying off.
Almost got that net profit rolling, looking forward to FY24! Plus, its really about GAAP and accounting, its not like they
are actually losing millions each year.
We are making it happen as we always knew.
Don't listen to the negative critics, they know nothing, they add nothing.
Lets go!
Great Annual! Almost 50% increase in revs, and we talking $9 Million! How rare is that pinks? :)
We will be off them in the future. For now, our engine keeps revving as we add locations and KPIs get better and better.
COGS is going down too it looks like! That is awesome, meaning all the efforts to streamline operations is really paying off.
Almost got that net profit rolling, looking forward to FY24! Plus, its really about GAAP and accounting, its not like they
are actually losing millions each year.
We are making it happen as we always knew.
Don't listen to the negative critics, they know nothing, they add nothing. The rhetoric of their cumulative bullshit amounts to nothing.
Haters gonna hate, and they only do because they themselves failed to succeed.
Lets go!
Looking forward to the annual this week! Revenues have come way up over the past couple of years. Looking good! Lots of great opportunity for the company as we continue to rise, adding locations, strengthening brand and continuing upward as we grow the company.
Great day, nice L2 shift. Volume up, funding initiative started. Going full SEC reporting and gearing up!
Decade ago posts being dredged. Lol I made a nice chunk of change on NRTI on the run to .32
Wow, dumb folks bringing up 10 year old posts, what kind of life they must lead
“If shown to be successful, this delivery method could be a “holy grail” for the psychedelic space, said Mike Zapolin — aka “Zappy” — the company’s former chief visionary officer and now adviser. No toxicities, no side effects, no withdrawal. And Zapolin, who can be a little evangelical about the delivery system’s potential, believes it could work similarly for even the most highly addictive prescription drugs like benzodiazepines and opioids.”
Love it!
Exactly, you would have to be a complete idiot to think Keith is CEO, BWVI has anything to do with treasure recovery anymore, or even refer back to it.
BUTT then again some morons CONvince themselves over and over they r so smart. Lol, just dumbass loser failure in life
Out of touch with reality, aging dinosaurs, DA wife hates them DA sun thinks whatta loser clown dad I got
so they sit around making friends with racoons and eating tina's burritos making shit up left and right trying to verify their life here and their super easily broken fragile ass tiny tiny tiny ego
Or, cuz you know they got no sense of intelligence, gotta plagiarize others cuz they can't be original.
garbage clown troll.
Psychopath stalker too. My god, can you think of anything more pathetic?
At least can't hide like a pussy coward clown anymore with the new rules, after spending years trying the game them, now we can tell it like it is
Well maybe not that but you are a moron if you think this a Pump and Dump. Go do some DD for like half a second.
Psycheceutical Bioscience Announces Completion of PCAOB Audit and Future Corporation Action Strategy
Press Release | 08/01/2023 Multi-year PCAOB audited financials completed
Company on the path to become fully SEC reporting
Future corporate action with name and symbol change
MIAMI, FL / ACCESSWIRE / August 1, 2023 / Psycheceutical Bioscience, Inc. ("Psycheceutical'' or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced that its auditors RBSM LLP have completed a PCAOB audit of the company's financial statements for the periods ending December 31, 2022 and 2021. With the completion of the audit, Psycheceutical is well-positioned to focus on its near-term fundraising plans, to strategize its process and timing for becoming a fully reporting company with the Securities and Exchange Commission (SEC), and to advance its strategic plans for aligning its corporate name and listing symbol.
"This is a major and long-awaited milestone for our organizational strategic objectives, as this audit process has covered both pre- and post-merger periods related to our merger in 2021 with Blue Water Ventures International," stated Chad Harman, CEO of Psycheceutical. "We are eager to advance key fundraising initiatives to support our ongoing drug development efforts, including the recent start of our Phase I clinical trial in Australia to study our novel NeuroDirectTM ketamine topical to treat PTSD."
The audited financial statements can be viewed here.
PCAOB Audit Completion
The audit completion and approval by RBSM LLP, a PCAOB registered accounting and auditing firm, provides third-party verification as to the accuracy of the company's financial statements. It is expected that the audit completion and process to become a fully reporting company with the SEC will provide an enhanced sense of confidence and transparency to current and potential shareholders moving forward.
Future Name and Symbol Change
The current Blue Water Ventures International name and BWVI ticker symbol came from a reverse merger into a treasure recovery holding company, which can be confusing to investors or anyone doing due diligence. The new name and symbol is the last important step in completing the organization changeover from the merger. It is critical that current and future investors understand Psycheceutical's brand and mission to advance its patented next-generation delivery technologies for the safe and effective treatment of mental health disorders. All focus will be on bringing new therapeutics and treatment options to the market.
As Psycheceutical makes progress on its organizational strategy, it is also making strides in advancing its drug development strategy. The company recently announced the successful dosing of the first patient in the historic Phase I clinical trial for its NeuroDirect ketamine topical as a treatment for individuals suffering from PTSD. Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder. As they look forward to the results of that study, the company will continue expanding its clinical trial program to other psychedelic medicines and treatment options for mental health and neurodegenerative disorders. See Psycheceutical's drug pipeline here.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. (OTC PINK: BWVI) is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and top neuroscientists, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Psycheceutical Bioscience, Inc.
press@psycheceutical.com
SOURCE: Psycheceutical Bioscience, Inc.
Nice News! Multi Year Audit complete! Going Full SEC: https://www.otcmarkets.com/stock/BWVI/news/Psycheceutical-Bioscience-Announces-Completion-of-PCAOB-Audit-and-Future-Corporation-Action-Strategy?id=409451
Looking Great, love Management is sticking to the posted plan on the website, and updating it. That first in clinical after the awesome preclinical data and write up is great. Certainly optimistic where this is going!
https://psycheceutical.com/pipeline/
Awesome they are working through a faster regulatory pathway as well!
The company has already achieved important milestones in its push to commercialize its unique product, with initial discussions held with the U.S. Food and Drug Administration (FDA) where a 505(b)(2) pathway has been identified for obtaining regulatory approvals.
Love this part: Multi-Billion Dollar PTSD Market
The global PTSD treatment market size was valued at $16.0 billion in 2021 and is projected to reach $26.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% (Vikita et al., 2022). With millions of people around the world suffering from PTSD, and no effective therapeutics currently available, Psychceutical's hope is that NeuroDirect ketamine could revolutionize the PTSD treatment market.
https://www.otcmarkets.com/stock/BWVI/news/First-Patient-Dosed-in-Psycheceuticals-Phase-I-Study-Exploring-Topical-Administration-of-Ketamine-to-Treat-PTSD?id=407406
$BWVI starting up clinical trials, bringing much needed medicine to the masses to combat the on going mental health crisis.
Nice News today!: First Patient Dosed in Psycheceutical's Phase I Study Exploring Topical Administration of Ketamine to Treat PTSD
Press Release | 07/13/2023
Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder through the company's NeuroDirect™ delivery system.
MIAMI, FL / ACCESSWIRE / July 13, 2023 / Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC PINK:BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced that the first patient has been dosed in its Phase I study to evaluate its patented NeuroDirect™ ketamine topical delivery system for the treatment of Post Traumatic Stress Disorder (PTSD). NeuroDirect ketamine is the company's first non-systemic drug candidate designed to target free nerve endings on the back of the neck, with the objective of delivering psychedelic medicines safely, effectively and without hallucinogenic effects.
The goal of the Phase I study, which is being conducted by iNGENÅ« Pty Ltd. in Australia, is to test the safety, tolerability, and pharmacokinetics of NeuroDirect ketamine in 24 healthy adult volunteers. Psycheceutical's clinical trial program is the first ever to test the topical application of ketamine for use in treating a mental health disorder.
"Today's achievement marks our transition to a clinical-stage company and represents an important milestone for Psycheceutical, and more importantly for those individuals who seek a safe, alternative therapy to improve their mental health," said Chad Harman, CEO of Psycheceutical. "With our goal of a non-systemic treatment for PTSD using legal ketamine, we are attempting to pave the way for our future drug candidates to treat other mental health disorders."
The Phase I clinical trial builds on the recent positive results of a observational preclinical study published in Drug Development and Delivery that describes the potential of NeuroDirect ketamine topical cream as an improved treatment for PTSD. In the study of 100 patients who hadn't responded to traditional therapies, more than 80% trying NeuroDirect ketamine topical found it effective at treating their symptoms. As described in the study, "Discernible improvement[s] in anxiety, depression, paranoia and unrealistic fear, focusing issues, cloudy thinking, neuropathic pain, and other such symptoms were noted within 8-10 minutes of topical drug application. No psychogenic effects, such as hallucinations or dissociative phenomena, were experienced by any patient. To the contrary, patients indicated their thought processes were clearer, more focused, and that they were more keenly aware of surroundings."
Multi-Billion Dollar PTSD Market
The global PTSD treatment market size was valued at $16.0 billion in 2021 and is projected to reach $26.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% (Vikita et al., 2022). With millions of people around the world suffering from PTSD, and no effective therapeutics currently available, Psychceutical's hope is that NeuroDirect ketamine could revolutionize the PTSD treatment market.
The company has already achieved important milestones in its push to commercialize its unique product, with initial discussions held with the U.S. Food and Drug Administration (FDA) where a 505(b)(2) pathway has been identified for obtaining regulatory approvals.
NeuroDirect™ for Non-Systemic Delivery
Psycheceutical's NeuroDirect™ non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. This delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results, while avoiding the systemic side effects of psychedelic compounds such as hallucinations, nausea, and dizziness. NeuroDirect™ is designed to be administered at home instead of a clinical setting, greatly lowering the cost of care for both insurance companies and patients, increasing access to these life-saving treatments for anyone suffering from mental health disorders or central nervous system diseases.
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. (OTC PINK:BWVI) is developing cutting-edge technologies to advance the safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a team of FDA drug development veterans, biotechnology experts, and top neuroscientists, Psycheceutical is on a mission to commercialize its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
press@psycheceutical.com
SOURCE: Psycheceutical, Inc.
Nice find! Like where the industry is headed. Looking forward to the next update!
$BWVI
Second letter has come, process is moving along!
Looking forward to the next steps for BWVI. The preclinical data is great and moving into the clinical studies. Great IP. Management and Industry. Much needed medicine for the clear mental crisis that is going on, we see evidence of it every day.
$BWVI
Apparently I am supposed to post every single sell I make on the board. Sure I'll publicly put out every trade I make on a public board, otherwise it didn't happen. lolol
For example:
FUNN bought below .02 sold high teens
SSFT MULTIPLE runs .04-.08 to .25-.40
BWVI .02 - .75
Yes, ALL my stocks have had good money opportunities, made great money and re-accumulated over time for the next run. All three of those examples all have great potential. My DD pays, why would anyone post every trade they make, that just isn't prudent. Sheesh. I guess there are folks out there who can't stand winners.
Yeah, such bs i buy a stock .03 and under post about my buys and a couple years later it runs to .75 and i take profits. Just such an unfathomable concept!
And now im accumulating again and have for awhile because i believe from my DD another nice run is coming. Folks are free to disagree and its otc so high risk by default. But if you look at my history ALL my stocks have had nice runs and money making opportunities.
So im just fine.
$BWVI
Such a simple thing to check my history… see I’ve been plenty buying under .10 2018-2021 and easy to see the run New Years Eve 2021 to .75.
Not a difficult concept.
So getting called rubbish when all the proof is there lolol
Im laughing because i spend my time making money and not worrying about what others want to believe. Why i have a nice successful career as well, and i keep my certifications and qualifications.
But what is great is the best is yet to come here, in my opinion.
Great company in Psycheceutical, IP and direction.
Love the preclinical data.
Great SS as well.
Looking great!
Clueless Statement. Due Diligence is a thing.
You mean the company that is generating millions in revenues and growing? You mean the company that has massive opportunity as leader in the BGC space? 7 Q in a row growth in the millions? And hasnt issued any new stock in a long time?
Yeah such a pos, terrible to have a company with such a future
$FUNN
Reality is a growing company generating millions in revenues with thousands of customers every single week. How many pinks do that? Oh yeah less than 1%
We have opportunities everywhere and will just keep growing. Closing the gap to profitability (tons of companies on big boards are in much worse financial shape than FUNN)
Leader in the industry, future is bright. Wont be on the pinks forever, for now just add locations and continue to optimize each one.
$FUNN
Its not. Hasnt been any new stock issues for a long time.
Looking forward to the next update.
$FUNN
False. Better DD needed from that statement
No new stock issued, no new deposits. Someone took a hit.
Happens.
$FUNN